Company Analysis

Tenax Therapeutics, Inc. (TENX)

Nasdaq: TENX · Pharmaceutical Preparations · Chapel Hill, NC · filing with the SEC since 1996
Grade5.1
◀ Past 3.2● Present 4.8▶ Future 6.5
6 est.

Who runs Tenax Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Giordano Christopher Thomas
CEO. First filing Jul 2021, latest Sep 15, 2026, 2 filings in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
21 people on the record since 2010
Officerssales are open-market, Oct 21, 2025 to Oct 21, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Giordano Christopher ThomasCEOJul 2021Sep 15, 2026none
Staab Thomas R IIChief Financial OfficerMay 2026Sep 15, 2026none
Mcgauley ThomasInterim CFODec 2024Feb 3, 2026none
Rich StuartChief Medical OfficerJan 2021Jan 13, 2026none
Directorssales are open-market, Oct 21, 2025 to Oct 21, 2026
NameRoleFirst filingLatest filingSales, 12 months
Doogan DeclandirectorJun 2021Sep 17, 2026none
Almenoff June SheriedirectorJun 2021Jan 13, 2026none
Davidson Michael H.directorJun 2021Jan 13, 2026none
Hunter RobyndirectorJan 2022Jan 13, 2026none
Proehl Gerald TdirectorNov 2016Jan 13, 2026none
Owners of more than 10% of a classsales are open-market, Oct 21, 2025 to Oct 21, 2026
NameRoleFirst filingLatest filingSales, 12 months
Adar1 Capital Management, LLC10% ownerAug 2026Oct 21, 2026none
Schneeberger Daniel10% ownerAug 2026Oct 21, 2026none
Earlier names on the record13, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton TENX · research, not advice